
Merck (MRK) financial statements
For the fiscal year ending 31 Dec 2025, Merck reported revenue of $65.0B and net income of $18.3B. Revenue grew 1.3% on the year before. Free cash flow was $12.4B. The latest quarter it has reported ended 30 Sep 2026.
Key figures for the fiscal year ending 31 Dec 2025
Margins are computed here from the reported figures: gross profit or operating income divided by revenue.
Annual statements
Income statement
| Year ending | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 | 31 Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.0B | $64.2B | $60.1B | $59.3B | $48.7B | $41.5B | $39.1B | $42.3B | $40.1B | $39.8B |
| Cost of revenue | $16.4B | $15.2B | $16.1B | $17.4B | $13.6B | $13.6B | $12.0B | $13.5B | $12.9B | $14.0B |
| Gross profit | $48.6B* | $49.0B* | $44.0B* | $41.9B* | $35.1B* | $27.9B* | $27.1B* | $28.8B* | $27.2B* | $25.8B* |
| Research & development | $15.8B | $17.9B | $30.5B | $13.5B | $12.2B | $13.4B | $9.7B | $9.8B | $10.3B | $10.3B |
| Selling, general & administrative | $10.7B | $10.8B | $10.5B | $10.0B | $9.6B | $9.0B | $9.5B | $10.1B | $10.1B | $10.0B |
| Income before tax | $21.1B | $19.9B | $1.9B | $16.4B | $13.9B | $5.9B | $7.2B | $8.7B | $6.5B | $4.7B |
| Income tax | $2.8B | $2.8B | $1.5B | $1.9B | $1.5B | $1.3B | $1.6B | $2.5B | $4.1B | $718.0M |
| Net income | $18.3B | $17.1B | $365.0M | $14.5B | $13.0B | $7.1B | $9.8B | $6.2B | $2.4B | $3.9B |
| EPS (basic) | $7.30 | $6.76 | $0.14 | $5.73 | $5.16 | $2.79 | $3.84 | $2.34 | $0.88 | $1.42 |
| EPS (diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.78 | $3.81 | $2.32 | $0.87 | $1.41 |
| Diluted shares (weighted) | 2.5B | 2.5B | 2.5B | 2.5B | 2.5B | 2.5B | 2.6B | 2.7B | 2.7B | 2.8B |
Balance sheet
| Year ending | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 | 31 Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14.6B | $13.3B | $6.9B | $12.8B | $8.2B | $8.2B | $9.9B | $8.0B | $6.1B | $6.5B |
| Short-term investments | $0 | $447.0M | $252.0M | $498.0M | $0 | $0 | $774.0M | $899.0M | $2.4B | $7.8B |
| Accounts receivable | $11.8B | $10.3B | $10.3B | $9.4B | $9.2B | $6.8B | $6.8B | $7.1B | $6.9B | $7.0B |
| Inventory | $6.7B | $6.1B | $6.4B | $5.9B | $6.0B | $5.6B | $6.0B | $5.4B | $5.1B | $4.9B |
| Total current assets | $43.5B | $38.8B | $32.2B | $35.7B | $30.3B | $27.8B | $27.5B | $25.9B | $24.8B | $30.6B |
| Total assets | $136.9B | $117.1B | $106.7B | $109.2B | $105.7B | $91.6B | $84.4B | $82.6B | $87.9B | $95.4B |
| Total current liabilities | $28.3B | $28.4B | $25.7B | $24.2B | $23.9B | $27.3B | $22.2B | $22.2B | $18.6B | $17.2B |
| Long-term debt | $46.8B | $34.5B | $33.7B | $28.7B | $30.7B | $25.4B | $22.7B | $19.8B | $21.4B | $24.3B |
| Shareholders' equity | $52.6B | $46.4B | $37.6B | $46.1B | $38.3B | $25.4B | $26.0B | $26.9B | $34.6B | $40.3B |
Cash flow
| Year ending | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 | 31 Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.5B | $21.5B | $13.0B | $19.1B | $13.1B | $7.6B | $8.9B | $10.9B | $6.5B | $10.4B |
| Capital expenditure | $4.1B | $3.4B | $3.9B | $4.4B | $4.4B | — | — | — | — | — |
| Investing cash flow | -$13.7B | -$7.7B | -$14.1B | -$5.0B | -$16.4B | -$9.2B | -$2.5B | $4.3B | $2.7B | -$3.2B |
| Financing cash flow | -$1.9B | -$7.0B | -$4.8B | -$9.1B | $3.1B | -$2.8B | -$8.9B | -$13.2B | -$10.0B | -$9.0B |
| Dividends paid | $8.2B | $7.8B | $7.4B | $7.0B | $6.6B | $6.2B | $5.7B | $5.2B | $5.2B | $5.1B |
| Share repurchases | $5.1B | $1.3B | $1.3B | $0 | $840.0M | $1.3B | $4.8B | $9.1B | $4.0B | $3.4B |
| Stock-based compensation | $820.0M | $761.0M | $645.0M | $541.0M | $479.0M | $441.0M | $388.0M | $348.0M | $312.0M | $300.0M |
| Free cash flow | $12.4B* | $18.1B* | $9.1B* | $14.7B* | $8.7B* | — | — | — | — | — |
Quarterly statements
Show the last 12 quarters
Income statement
Balance sheet
| Quarter ending | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 | 30 Sep 2025 | 30 Jun 2025 | 31 Mar 2025 | 31 Dec 2024 | 30 Sep 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.6B | $6.8B | $5.3B | $14.6B | $18.3B | $8.1B | $8.7B | $13.3B | $14.7B | $11.4B | $5.7B | $6.9B |
| Short-term investments | $100.0M | $292.0M | $375.0M | $0 | $45.0M | $615.0M | $599.0M | $447.0M | $0 | $50.0M | $40.0M | $252.0M |
| Accounts receivable | $12.7B | $12.6B | $12.2B | $11.8B | $12.1B | $11.8B | $10.8B | $10.3B | $11.4B | $11.6B | $11.4B | $10.3B |
| Inventory | $6.2B | $6.2B | $6.5B | $6.7B | $6.4B | $6.6B | $6.2B | $6.1B | $6.2B | $6.5B | $6.5B | $6.4B |
| Total current assets | $38.9B | $36.7B | $35.0B | $43.5B | $47.6B | $37.1B | $35.5B | $38.8B | $40.4B | $38.2B | $31.4B | $32.2B |
| Total assets | $132.8B | $129.8B | $128.7B | $136.9B | $129.5B | $117.5B | $115.1B | $117.1B | $117.5B | $112.6B | $105.8B | $106.7B |
| Total current liabilities | $28.8B | $27.7B | $26.9B | $28.3B | $28.6B | $26.0B | $25.2B | $28.4B | $29.6B | $26.1B | $25.1B | $25.7B |
| Long-term debt | $49.7B | $51.1B | $46.7B | $46.8B | $40.0B | $34.0B | $33.5B | $34.5B | $35.0B | $34.7B | $31.1B | $33.7B |
| Shareholders' equity | $44.9B | $42.0B | $45.9B | $52.6B | $51.9B | $49.1B | $48.4B | $46.4B | $44.6B | $43.6B | $40.4B | $37.6B |
Cash flow
| Quarter ending | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 | 30 Sep 2025 | 30 Jun 2025 | 31 Mar 2025 | 31 Dec 2024 | 30 Sep 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.6B* | $5.4B* | $3.9B | $2.9B* | $7.8B* | $3.3B* | $2.5B | $3.5B* | $9.3B* | $5.6B* | $3.1B | $246.0M* |
| Capital expenditure | $1.0B* | $893.0M* | $991.0M | $1.0B* | $987.0M* | $764.0M* | $1.3B | $937.0M* | $783.0M* | $791.0M* | $861.0M | $989.0M* |
| Investing cash flow | -$1.3B* | -$5.6B* | -$10.2B | -$11.2B* | -$283.0M* | -$770.0M* | -$1.5B | -$1.4B* | -$3.8B* | -$1.1B* | -$1.4B | $53.0M* |
| Financing cash flow | -$2.4B* | $1.8B* | -$3.0B | $4.8B* | $2.6B* | -$3.6B* | -$5.8B | -$3.0B* | -$2.4B* | $1.2B* | -$2.8B | -$2.2B* |
| Dividends paid | $2.1B* | $2.1B* | $2.1B | $2.0B* | $2.0B* | $2.1B* | $2.0B | $2.0B* | $2.0B* | $2.0B* | $1.9B | $1.9B* |
| Share repurchases | $653.0M* | $757.0M* | $874.0M | $1.3B* | $1.3B* | $1.3B* | $1.2B | $489.0M* | $444.0M* | $251.0M* | $122.0M | $393.0M* |
| Stock-based compensation | $369.0M* | $298.0M* | $185.0M | $205.0M* | $204.0M* | $216.0M* | $195.0M | $187.0M* | $195.0M* | $203.0M* | $176.0M | $167.0M* |
| Free cash flow | $5.5B* | $4.5B* | $2.9B* | $1.8B* | $6.8B* | $2.5B* | $1.2B* | $2.5B* | $8.5B* | $4.8B* | $2.2B* | -$743.0M* |
Where these figures come from
Every figure is read from the XBRL data Merck files with the SEC in its 10-K and 10-Q reports: US GAAP, in US dollars, as last reported, so a restated figure replaces the original. Each one links to the filing it came from.
Figures in italics with * were derived from reported ones (hover for how): no filing reports a fourth quarter on its own, so it is the fiscal year minus the first nine months, and free cash flow is operating cash flow minus capital expenditure. Per-share figures and share counts are never derived.
SEC's XBRL data for this companyResearch Merck in MALI
Six AI agents argue the bull and the bear case from the filings, prices and news, and every call MALI makes is scored in its public track record. The Starter plan is free.